News & Updates
Filter by Specialty:
Could tixagevimab–cilgavimab prevent progression to severe COVID-19 in unvaccinated adults?
The combination of tixagevimab and cilgavimab, two SARS-CoV-2 neutralizing monoclonal antibodies, appeared to protect against progression to severe disease or death in non-hospitalized, unvaccinated adults presenting with mild-to-moderate COVID-19, results of the ongoing phase III TACKLE trial showed.
Could tixagevimab–cilgavimab prevent progression to severe COVID-19 in unvaccinated adults?
01 Sep 2022Combined oral contraceptives and VTE: Which pill conveys the highest risk in young women?
Combined oral contraceptives (COCs) that contain gestodene confer a fivefold increased risk of venous thromboembolism (VTE) in young women as compared with those that contain levonorgestrel and the lowest doses of ethinylestradiol, as shown in a study.
Combined oral contraceptives and VTE: Which pill conveys the highest risk in young women?
29 Aug 2022Add-on pembrolizumab–tocilizumab combo reduces hospitalization period in severe COVID-19
In the treatment of patients with severe COVID-19, adding the combination of pembrolizumab plus tocilizumab to standard of care (SOC) appears to result in higher and faster discharge from the hospital without sequelae, as shown in the proof-of-concept phase II COPERNICO trial.